Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:MNTA's Cash-to-Debt is ranked higher than
100% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NAS:MNTA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MNTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.74  Med: 117.59 Max: No Debt
Current: No Debt
Equity-to-Asset 0.72
NAS:MNTA's Equity-to-Asset is ranked higher than
61% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:MNTA: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MNTA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.85 Max: 0.96
Current: 0.72
-0.49
0.96
Interest Coverage No Debt
NAS:MNTA's Interest Coverage is ranked higher than
99% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. NAS:MNTA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:MNTA' s Interest Coverage Range Over the Past 10 Years
Min: 110.84  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 4.57
Beneish M-Score: -4.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -87.38
NAS:MNTA's Operating Margin % is ranked lower than
85% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. NAS:MNTA: -87.38 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MNTA' s Operating Margin % Range Over the Past 10 Years
Min: -448.33  Med: -142.21 Max: 63.48
Current: -87.38
-448.33
63.48
Net Margin % -39.35
NAS:MNTA's Net Margin % is ranked lower than
81% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. NAS:MNTA: -39.35 )
Ranked among companies with meaningful Net Margin % only.
NAS:MNTA' s Net Margin % Range Over the Past 10 Years
Min: -429.9  Med: -140.82 Max: 63.71
Current: -39.35
-429.9
63.71
ROE % -12.48
NAS:MNTA's ROE % is ranked lower than
76% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NAS:MNTA: -12.48 )
Ranked among companies with meaningful ROE % only.
NAS:MNTA' s ROE % Range Over the Past 10 Years
Min: -66.11  Med: -31.66 Max: 59.21
Current: -12.48
-66.11
59.21
ROA % -9.41
NAS:MNTA's ROA % is ranked lower than
76% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NAS:MNTA: -9.41 )
Ranked among companies with meaningful ROA % only.
NAS:MNTA' s ROA % Range Over the Past 10 Years
Min: -51.08  Med: -27.29 Max: 55.62
Current: -9.41
-51.08
55.62
ROC (Joel Greenblatt) % -429.40
NAS:MNTA's ROC (Joel Greenblatt) % is ranked lower than
88% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. NAS:MNTA: -429.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MNTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -529.82  Med: -376.75 Max: 349.83
Current: -429.4
-529.82
349.83
3-Year Revenue Growth Rate 31.80
NAS:MNTA's 3-Year Revenue Growth Rate is ranked higher than
92% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NAS:MNTA: 31.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:MNTA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.8 Max: 139.6
Current: 31.8
0
139.6
3-Year EBITDA Growth Rate -21.70
NAS:MNTA's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:MNTA: -21.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:MNTA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.2  Med: -9 Max: 30.4
Current: -21.7
-45.2
30.4
3-Year EPS without NRI Growth Rate -47.40
NAS:MNTA's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. NAS:MNTA: -47.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:MNTA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.2  Med: -9.6 Max: 30.1
Current: -47.4
-48.2
30.1
GuruFocus has detected 3 Warning Signs with Momenta Pharmaceuticals Inc $NAS:MNTA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MNTA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MNTA Guru Trades in Q3 2016

Paul Tudor Jones 19,731 sh (New)
PRIMECAP Management 2,739,900 sh (+0.04%)
Jim Simons 292,800 sh (-19.71%)
» More
Q4 2016

MNTA Guru Trades in Q4 2016

Jim Simons 397,100 sh (+35.62%)
Paul Tudor Jones 23,129 sh (+17.22%)
PRIMECAP Management 2,739,900 sh (unchged)
» More
Q1 2017

MNTA Guru Trades in Q1 2017

PRIMECAP Management 2,739,900 sh (unchged)
Paul Tudor Jones 19,100 sh (-17.42%)
Jim Simons 278,400 sh (-29.89%)
» More
Q2 2017

MNTA Guru Trades in Q2 2017

Jim Simons 797,400 sh (+186.42%)
PRIMECAP Management 2,839,900 sh (+3.65%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325414    SIC: 2836
Compare:NYSE:DPLO, NAS:PAHC, NAS:RDUS, NAS:PCRX, NAS:IPXL, NAS:EGRX, NAS:HRTX, NAS:FLXN, NAS:AMPH, NYSE:LCI, NAS:SGYP, NAS:SCLN, NAS:SCMP, NAS:KPTI, NAS:ADMS, NAS:DEPO, NAS:TLGT, NAS:TTPH, NAS:PETQ, NAS:ACET » details
Traded in other countries:LZ1.Germany,
Headquarter Location:USA
Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.

Momenta is a biotechnology company based in Cambridge, Mass. Using technology developed at the Massachusetts Institute of Technology, it focuses on the characterization and development of innovative and complex generic drug molecules. Its first and only product is a bioequivalent generic version of Lovenox, sold through a partnership with Novartis. The company received an approval for a generic version of Copaxone in early 2015 and has other innovative biologic drugs and biosimilars under development.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 44.01
MNTA's Price-to-Owner-Earnings is ranked lower than
60% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. MNTA: 44.01 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNTA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.23  Med: 9.16 Max: 47.14
Current: 44.01
3.23
47.14
PB Ratio 3.26
MNTA's PB Ratio is ranked lower than
58% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. MNTA: 3.26 )
Ranked among companies with meaningful PB Ratio only.
MNTA' s PB Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.98 Max: 13.69
Current: 3.26
1.34
13.69
PS Ratio 10.44
MNTA's PS Ratio is ranked lower than
80% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MNTA: 10.44 )
Ranked among companies with meaningful PS Ratio only.
MNTA' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 13.52 Max: 57.26
Current: 10.44
1.84
57.26
Price-to-Free-Cash-Flow 24.14
MNTA's Price-to-Free-Cash-Flow is ranked higher than
56% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. MNTA: 24.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MNTA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.02  Med: 10.33 Max: 622.58
Current: 24.14
3.02
622.58
Price-to-Operating-Cash-Flow 20.98
MNTA's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. MNTA: 20.98 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MNTA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.92  Med: 9.44 Max: 170.8
Current: 20.98
2.92
170.8
EV-to-EBIT -8.52
MNTA's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. MNTA: -8.52 )
Ranked among companies with meaningful EV-to-EBIT only.
MNTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -52.4  Med: -4.7 Max: 16.9
Current: -8.52
-52.4
16.9
EV-to-EBITDA -9.29
MNTA's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. MNTA: -9.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.3  Med: -5 Max: 15
Current: -9.29
-80.3
15
EV-to-Revenue 7.44
MNTA's EV-to-Revenue is ranked lower than
72% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. MNTA: 7.44 )
Ranked among companies with meaningful EV-to-Revenue only.
MNTA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 9.4 Max: 55.2
Current: 7.44
0.9
55.2
Current Ratio 4.08
MNTA's Current Ratio is ranked higher than
70% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MNTA: 4.08 )
Ranked among companies with meaningful Current Ratio only.
MNTA' s Current Ratio Range Over the Past 10 Years
Min: 4.08  Med: 10.47 Max: 28.87
Current: 4.08
4.08
28.87
Quick Ratio 4.08
MNTA's Quick Ratio is ranked higher than
76% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. MNTA: 4.08 )
Ranked among companies with meaningful Quick Ratio only.
MNTA' s Quick Ratio Range Over the Past 10 Years
Min: 4.08  Med: 10.47 Max: 28.87
Current: 4.08
4.08
28.87
Days Sales Outstanding 79.76
MNTA's Days Sales Outstanding is ranked lower than
57% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. MNTA: 79.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.32  Med: 86.25 Max: 233.89
Current: 79.76
36.32
233.89

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.80
MNTA's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. MNTA: -10.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -218.2  Med: -10.45 Max: -1.7
Current: -10.8
-218.2
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.30
MNTA's Price-to-Net-Cash is ranked higher than
81% of the 239 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.21 vs. MNTA: 4.30 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MNTA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.03  Med: 4.05 Max: 14.33
Current: 4.3
2.03
14.33
Price-to-Net-Current-Asset-Value 3.83
MNTA's Price-to-Net-Current-Asset-Value is ranked higher than
75% of the 512 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. MNTA: 3.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MNTA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.55  Med: 3.55 Max: 11.36
Current: 3.83
1.55
11.36
Price-to-Tangible-Book 3.29
MNTA's Price-to-Tangible-Book is ranked higher than
52% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. MNTA: 3.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MNTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.5  Med: 3.08 Max: 10.13
Current: 3.29
1.5
10.13
Price-to-Intrinsic-Value-Projected-FCF 9.26
MNTA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
68% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MNTA: 9.26 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MNTA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.77  Med: 4 Max: 9.61
Current: 9.26
1.77
9.61
Price-to-Median-PS-Value 0.77
MNTA's Price-to-Median-PS-Value is ranked higher than
81% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. MNTA: 0.77 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNTA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.05 Max: 4.01
Current: 0.77
0.14
4.01
Earnings Yield (Greenblatt) % -11.75
MNTA's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MNTA: -11.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNTA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -158.2  Med: -16.95 Max: 78.3
Current: -11.75
-158.2
78.3

More Statistics

Revenue (TTM) (Mil) $113.52
EPS (TTM) $ -0.62
Beta1.91
Short Percentage of Float9.26%
52-Week Range $10.75 - 19.90
Shares Outstanding (Mil)76.23

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 142 185 190 292
EPS ($) -1.36 -0.93 -1.31 1.18
EPS without NRI ($) -1.36 -0.93 -1.31 1.18
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors Sep 12 2017 
Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference Aug 30 2017 
Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update Aug 02 2017 
Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Agai Jul 21 2017 
Momenta Pharmaceuticals Announces Date of Second Quarter 2017 Financial Results Conference Call and Jul 19 2017 
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare C Jun 07 2017 
Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer Jun 01 2017 
UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 10 2017 
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 10 2017 
Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results May 02 2017 

More From Other Websites
Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors Sep 12 2017
See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Sep 07 2017
Momenta (MNTA) Up 5.8% Since Earnings Report: Can It Continue? Sep 06 2017
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US :... Sep 01 2017
Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference Aug 30 2017
Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : August 12, 2017 Aug 11 2017
Edited Transcript of MNTA earnings conference call or presentation 2-Aug-17 2:00pm GMT Aug 11 2017
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US :... Aug 10 2017
IHS Markit Score downgrades Momenta Pharmaceuticals Inc to 30 out of 100, ranking positively in only... Aug 10 2017
Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat Aug 03 2017
Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter Aug 03 2017
Momenta reports 2Q loss Aug 02 2017
Investor Network: Momenta Pharmaceuticals, Inc. to Host Earnings Call Aug 02 2017
Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update Aug 02 2017
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US :... Jul 28 2017
U.S. jury sides with Amphastar over Momenta in drug patent trial Jul 21 2017
​Jury nixes Momenta patent case that sought $938M in damages Jul 21 2017
Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation... Jul 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}